Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 334 in Healthy Subjects and in Migraine Patients
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Amgen
- 18 Dec 2019 Results of pooled analysis (NCT02066415, NCT02456740, NCT01952574, NCT02483585, NCT02174861, and NCT01723514) assessing the cardiovascular, cerebrovascular, and peripheral vascular safety of erenumab across migraine prevention studies published in the Neurology
- 24 Jul 2017 Results of this and other study (NCT01688739) published in the Clinical Pharmacology and Therapeutics Journal.
- 21 Jun 2015 Results presented at the 57th Annual Scientific Meeting of the American Headache Society.